HUONS CO., LTD.
KOSDAQ-listed pharmaceutical and healthcare company producing lidocaine anesthetics and the Kynix hyaluronic-acid eye-drop line.
As of 2026-10-10, HUONS CO., LTD. has 6 Korean MFDS device approvals, 580 Korean MFDS drug approvals, 2 US FDA clearances/approvals, 57 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureEstablished in 2016 and listed on KOSDAQ in 2016, Huons is a pharmaceutical and healthcare company. It manufactures lidocaine local anesthetics, the Kynix hyaluronic-acid eye drop line, and the Merit series of high-dose vitamin injections and health functional foods, spanning prescription drugs, beauty/wellness, and CMO contract manufacturing. Through its Jecheon plant (built 2009) and second plant (completed 2022, GMP-certified August 2023), it exports lidocaine and other injectables under US FDA ANDA approvals, and expanded into biosimilars and CDMO by acquiring a stake in Pangen in December 2024, which became a subsidiary in June 2025.
Products & technology
- Lidocaine local anestheticLocal anesthesia
- Kynix (hyaluronic acid eye drop)Ophthalmic eye-drop treatment
- Merit series (high-dose vitamin injections and health functional foods)Beauty and wellness
Regulatory approvals
data.go.kr · openFDA580 Korean MFDS drug approvals · 1970–2026 / 6 Korean MFDS device approvals · 2011–2020 / 2 US FDA drug approvals · 2019–2020
- MFDS drugHudarbi tab. 80mg(Azilsartan Medoxomil Potassium)2026-09-07Drug · Prescription · Approval202602656
- MFDS drugHudoxa Tab. 60mg(Edoxaban Tosylate Hydrate)2026-08-31Drug · Prescription · Approval202602547
- MFDS drugHudoxa Tab. 30mg(Edoxaban Tosylate Hydrate)2026-08-31Drug · Prescription · Approval202602554
- MFDS drugHuons Atorvastatin Tab. 5mg (Atorvastatin calcium trihydrate)2026-08-25Drug · Prescription · Approval202602458
- MFDS drugHutava ODT 2mg(Pitavasatin Calcium Hydrate)2026-07-30Drug · Prescription · Approval202602220
- MFDS drugHutava ODT 4mg(Pitavastatin Calcium Hydrate)2026-07-30Drug · Prescription · Approval202602221
- MFDS drugHuons Dexketoprofen Inj. (Dexketoprofen trometamol)2026-07-27Drug · Prescription · Approval202602157
- MFDS drugLUMIEJU PDRN CREAM(Polydeoxyribonucleotide Sodium)2026-06-29Drug · OTC · Notification202601831
- MFDS drugBesylsartan Q Tab. 5/100/5mg(Amlodipine besylate, losartan potassium, rosuvastatin calcium)2026-06-15Drug · Prescription · Approval202601697
- MFDS drugHupran Tab. 50mg(Pranlukast hydrate)2026-05-22Drug · Prescription · Approval202601490
- MFDS drugHunoxidil Tab. 5mg (Minoxidil)2026-02-26Drug · Prescription · Approval202600590
- MFDS drugPrega ODT 75mg2026-02-24Drug · Prescription · Approval202600536
Show 68 more
- MFDS drugPrega ODT 50mg2026-02-24Drug · Prescription · Approval202600537
- MFDS drugPrega ODT 150mg2026-02-24Drug · Prescription · Approval202600538
- MFDS drugRocatan Tab. 25mg (Losartan potassium)2025-12-24Drug · Prescription · Approval202503377
- MFDS drugLidocaine HCl Injection 2%2025-12-23Drug · Prescription · Approval202503365
- MFDS drugMucoramin SR Tablet 150mg (Rebamipide)2025-12-09Drug · Prescription · Approval202503222
- MFDS drugMigslim Tab. 50mg (Miglitol)2025-12-08Drug · Prescription · Approval202503191
- MFDS drugHUAMINA Tab.2025-11-28Drug · OTC · Notification202503122
- MFDS drugSacchalus-duo Cap.2025-10-13Drug · OTC · Notification202502638
- MFDS drugHUBACTAM Inj. 2.25g (Piperacillin SodiumTazobactam Sodium)2025-10-02Drug · Prescription · Approval202502624
- MFDS drugBesylsartan Q Tab. 5/100/10mg(Amlodipine besylate, losartan potassium, rosuvastatin calcium)2025-09-19Drug · Prescription · Approval202502493
- MFDS drugBesylsartan Q Tab. 5/50/10mg(Amlodipine besylate, losartan potassium, rosuvastatin calcium)2025-09-19Drug · Prescription · Approval202502494
- MFDS drugMerit G Inj. (N(2)-L-alanyl-L-glutamine)2025-09-09Drug · Prescription · Approval202502388
- MFDS drugNizoral 1% Sol. (Ketoconazole)2025-08-13Drug · OTC · Approval202502089
- MFDS drugLIVAFENON Cap. 2/160mg (Pitavastatin calcium,Fenofibrate)2025-07-11Drug · Prescription · Approval202501757
- MFDS drugHuperaflu Inj.2025-07-09Drug · Prescription · Approval202501732
- MFDS drugHurotadine Eye Drops 0.7% (Olopatadine hydrochloride)2025-07-09Drug · Prescription · Approval202501734
- MFDS drugHUDIANCE Duo XR Tab. 5/1000mg (Empagliflozin,Metformin)2025-07-01Drug · Prescription · Approval202501631
- MFDS drugHUDIANCE Duo XR Tab. 12.5/1000mg (Empagliflozin,Metformin)2025-07-01Drug · Prescription · Approval202501632
- MFDS drugHUDIANCE Duo XR Tab. 10/1000mg (Empagliflozin,Metformin)2025-06-23Drug · Prescription · Approval202501552
- MFDS drugHUDIANCE Duo XR Tab. 25/1000mg (Empagliflozin,Metformin)2025-06-23Drug · Prescription · Approval202501553
- MFDS drugHurapang tab.2025-06-20Drug · Prescription · Approval202501528
- MFDS drugDreamel PR tab. 2mg (Melatonin)2025-04-22Drug · Prescription · Approval202500950
- MFDS drugHUSIGLOM SR Tab. 5/50/1000mg2025-03-27Drug · Prescription · Approval202500711
- MFDS drugCal-D-Up BD Tab.2025-03-27Drug · OTC · Notification202500721
- MFDS drugHurotadine Eye Drops 0.2% (Olopatadine hydrochloride)(single-dose), Hurotadine Eye Drops 0.2% (Olopatadine hydrochloride)2025-01-13Drug · Prescription · Approval202500100
- MFDS drugHUSIGLOM SR Tab. 10/100/1000mg2025-01-08Drug · Prescription · Approval202500060
- MFDS drugSatie SR Tab. 25mg (Topiramate)2024-12-16Drug · Prescription · Approval202402973
- MFDS drugSatie SR Tab. 50mg (Topiramate)2024-11-29Drug · Prescription · Approval202402828
- MFDS drugHu-liem Tab. 10/5mg2024-10-21Drug · Prescription · Approval202402465
- MFDS drugHu-liem Tab. 25/5mg2024-10-21Drug · Prescription · Approval202402466
- MFDS drugHusetan Tab(Sevelamer carbonate)2024-10-15Drug · Prescription · Approval202402436
- MFDS drugAmiceta Powder 500mg(Acetaminophen)2024-10-02Drug · OTC · Notification202402363
- MFDS drugAsrabe Cap.100/5mg(Aspirin,Rabeprazole)2024-09-30Drug · Prescription · Approval202402347
- MFDS drugCergol Tab. 10mg (Nicergoline)2024-09-26Drug · Prescription · Approval202402318
- MFDS drugSubsidiary: 휴온스생명과학(주)Huchlohexdin Sol. 0.12%(Chlorhexidine Gluconate Solution)Revoked2024-06-05Drug · OTC · Notification202401396
- MFDS drugEfirush topical solution (Efinaconazole)2024-04-29Drug · Prescription · Approval202401007
- MFDS drugGinkgobal Tab. 240mg (Ginkgo leaf drided extract)2024-04-24Drug · OTC · Notification202400966
- MFDS drugHuons Isoproterenol Hydrochloride Inj.2024-04-16Drug · Prescription · Approval202400863
- MFDS drugLinaD4 Duo XR Tab. 5/1000mg (Linagliptin, Metformin)2024-03-18Drug · Prescription · Approval202400567
- MFDS drugLinaD4 Duo XR Tab. 2.5/1000mg (Linagliptin, Metformin)2024-03-18Drug · Prescription · Approval202400569
- MFDS drugCergol Tab. 30mg (Nicergoline)2024-02-28Drug · Prescription · Approval202400418
- MFDS drugAperin Plus B Tab.2024-02-21Drug · OTC · Notification202400374
- MFDS drugAperin Plus BC Tab.2024-02-21Drug · OTC · Notification202400375
- MFDS drugNiotin Tab.2023-12-20Drug · OTC · Notification202303390
- MFDS drugHuvnac Eye drops (Bromfenac sodium hydrate)2023-10-30Drug · Prescription · Approval202303028
- MFDS drugEasymantine Tab. 20mg (Memantine hydrochloride)2023-10-26Drug · Prescription · Approval202302992
- MFDS drugLevomon Tab.(Montelukast Sodium, Levocetirizine Hydrochloride)2023-08-30Drug · Prescription · Approval202302551
- MFDS drugHusiglo Tab. (Dapagliflozin,Sitagliptin)2023-06-29Drug · Prescription · Approval202302005
- MFDS drugHuglia M Tablet 50/500 mg2023-03-13Drug · Prescription · Approval202300848
- MFDS drugHuglia M Tablet 50/850 mg2023-03-13Drug · Prescription · Approval202300849
- MFDS drugHuglia M Tablet 50/1000 mg2023-03-13Drug · Prescription · Approval202300850
- MFDS drugMOISTA CMC EYE DROPS 1.0%2023-03-08Drug · OTC · Notification202300801
- MFDS drugHuglia M XR Tablet 50/500 mg2023-02-17Drug · Prescription · Approval202300602
- MFDS drugHuglia M XR Tablet 50/1000 mg2023-02-17Drug · Prescription · Approval202300603
- MFDS drugHuglia M XR Tablet 100/1000 mg2023-02-17Drug · Prescription · Approval202300604
- MFDS drugHuxiga Tab. 10mg(Dapagliflozin propanediol hydrate)2023-01-30Drug · Prescription · Approval202300390
- MFDS drugHuxigaduo XR Tab. 10/500mg(Dapagliflozin, Metformin)2023-01-27Drug · Prescription · Approval202300359
- MFDS drugHuxigaduo XR Tab. 10/1000mg(Dapagliflozin, Metformin)2023-01-27Drug · Prescription · Approval202300360
- MFDS drugAmonosin-A inj.2022-12-28Drug · Prescription · Approval202204682
- MFDS drugSubsidiary: 휴온스생명과학(주)Inbro Tab.Revoked2022-11-16Drug · OTC · Notification202204128
- MFDS drugHutomega Soft Cap. 5/1000mg (Atorvastatin, Omega 3 acid ethyl esters 90)Revoked2022-07-08Drug · Prescription · Approval202202838
- MFDS drugAzelopine Tab. 16mg (Azelnidipine)2022-06-13Drug · Prescription · Approval202202477
- MFDS drugHuons Amino Injection 3%2022-06-10Drug · Prescription · Notification202202413
- MFDS drugHULEVO Eye drops 1.5%2022-05-16Drug · Prescription · Approval202202084
- MFDS drugAmoburofen premix Inj. (ibuprofen)2022-04-28Drug · Prescription · Approval202201732
- MFDS drugHurion Inj. (Sugammadex sodium)2022-01-28Drug · Prescription · Approval202200511
- MFDS drugAzelopine Tab. 8mg (Azelnidipine)2021-12-27Drug · Prescription · Approval202108116
- MFDS drugDobeonce Tab. 500mg (Calcium Dobesilate hydrate)2021-10-06Drug · Prescription · Approval202106754
Showing the 80 most recent of 588 records.
Clinical trials
data.go.kr142 MFDS clinical trial authorisations · 2012–2026 (Bioequivalence 96 · Phase 1 34 · Phase 3 7 · Phase 2 3 · Phase 1/2a 1)
- Phase 1HUC3A-7262026-09-22
2 trial sites
- Phase 1HUC2A-7522026-08-04
2 trial sites
- Phase 1HUC2-7442026-07-24
2 trial sites
- BioequivalenceHUC3-7172026-07-07
2 trial sites
- Phase 1HUC2-6762026-06-16
2 trial sites
- BioequivalenceHUC3-6712026-04-27
2 trial sites
- Phase 2HUC1-3942026-03-11
10 trial sites
- Phase 1HUC2-6762025-12-16
2 trial sites
- BioequivalenceHUC3-6462025-12-01
2 trial sites
- Phase 1HUC2-5882025-11-28
2 trial sites
- Phase 1HUC3-6602025-11-28
2 trial sites
- Phase 1HUC2-5882025-11-27
2 trial sites
Show 68 more
- Phase 1HUC3-6602025-11-27
2 trial sites
- BioequivalenceHUC3-5312025-10-27
2 trial sites
- BioequivalenceHUC3-5312025-10-27
2 trial sites
- BioequivalenceHUC3-6232025-07-18
2 trial sites
- BioequivalenceHUC3-6392025-06-02
2 trial sites
- BioequivalenceHUC3-6522025-05-26
2 trial sites
- Phase 3HUC3-6372025-04-22
20 trial sites
- BioequivalenceHUC3-5622025-01-10
2 trial sites
- BioequivalenceHUC3-5562024-12-31
2 trial sites
- BioequivalenceHUC3-5722024-11-01
2 trial sites
- BioequivalenceHUC3-5392024-10-14
2 trial sites
- BioequivalenceHUC3-5782024-09-11
1 trial site
- Phase 1HUC2-3642024-09-04
1 trial site
- BioequivalenceHUC3-5332024-05-28
2 trial sites
- BioequivalenceHUC3-5372024-05-22
1 trial site
- BioequivalenceHUC3-5332024-05-07
2 trial sites
- Phase 1HUC3-4312024-03-26
1 trial site
- Phase 1HUC2-5652024-02-19
1 trial site
- Phase 1HUC1-3942024-01-05
1 trial site
- Phase 1HUC2-3442024-01-02
1 trial site
- Phase 1HUC2-3442024-01-02
1 trial site
- BioequivalenceHUC3-5122023-11-03
2 trial sites
- Phase 3카이닉스3점안액(히알루론산나트륨)(1회용)2023-10-31
10 trial sites
- BioequivalenceHUC3-1392023-08-28
2 trial sites
- Phase 1HUC3-4312023-05-22
1 trial site
- BioequivalenceHUC3-5132023-04-04
2 trial sites
- BioequivalenceHUC3-0402023-04-04
2 trial sites
- BioequivalenceHUC3-2832023-03-10
2 trial sites
- Phase 1HUC2-3442023-03-08
1 trial site
- BioequivalenceHUC3-3372023-01-09
2 trial sites
- BioequivalenceHUC3-3372023-01-09
2 trial sites
- Phase 3HU0072022-11-30
10 trial sites
- BioequivalenceHUC3-3302022-11-08
2 trial sites
- Phase 1HUC2-3442022-10-27
1 trial site
- BioequivalenceHUC3-2972022-09-29
2 trial sites
- BioequivalenceHUC3-2972022-09-29
2 trial sites
- Phase 1HUC2-3642022-07-14
1 trial site
- Phase 1HUC3-4312022-06-21
1 trial site
- Phase 1HUC3-4432022-06-21
1 trial site
- BioequivalenceHUC3-3502022-05-31
2 trial sites
- Phase 1HUC3-3422022-05-10
1 trial site
- BioequivalenceHUC3-0662022-04-11
2 trial sites
- BioequivalenceHUC3-3832022-04-07
2 trial sites
- Phase 1HUC2-3962022-04-01
1 trial site
- Phase 1HUC2-3962022-04-01
1 trial site
- BioequivalenceHUC3-1392022-01-14
2 trial sites
- BioequivalenceHUC3-4302022-01-14
2 trial sites
- BioequivalenceHUC3-3122021-12-01
2 trial sites
- BioequivalenceHUC3-3372021-12-01
2 trial sites
- BioequivalenceHUC3-3612021-11-17
2 trial sites
- BioequivalenceHUC3-3572021-10-20
2 trial sites
- BioequivalenceHUC3-3012021-09-10
2 trial sites
- BioequivalenceHUC3-4132021-09-09
2 trial sites
- BioequivalenceHUC3-3782021-08-11
2 trial sites
- BioequivalenceHUC3-3782021-08-10
2 trial sites
- BioequivalenceHUC3-3772021-06-16
2 trial sites
- BioequivalenceHUC3-3772021-06-14
2 trial sites
- Phase 1HUC2-3962021-06-14
1 trial site
- BioequivalenceHUC3-3062021-05-25
2 trial sites
- BioequivalenceHUC3-3762021-05-12
2 trial sites
- BioequivalenceHUC3-3752021-05-12
2 trial sites
- BioequivalenceHUC3-3762021-05-12
2 trial sites
- BioequivalenceHUC3-3512021-04-07
2 trial sites
- BioequivalenceHUC3-3722021-02-05
2 trial sites
- BioequivalenceHUC3-3712021-02-05
2 trial sites
- BioequivalenceHUC3-3742021-01-15
2 trial sites
- BioequivalenceHUC3-3502021-01-11
2 trial sites
- BioequivalenceHUC3-3312020-12-17
2 trial sites
Showing the 80 most recent of 142 records.
Global clinical trials
ClinicalTrials.gov · sponsor-matchedPhase 1 · Not yet recruiting · 2026-10 · NCT07784621
Phase 1 · Not yet recruiting · 2026-09 · NCT07784608
Phase 2 · Recruiting · 2026-07 · NCT07656688
Phase 1 · Not yet recruiting · 2026-01 · NCT07337174
Phase 3 · Recruiting · 2026-01 · NCT07335211
Phase 1 · Unknown · 2024-07 · NCT06263998
Phase 3 · Completed · 2024-05 · NCT06388070
Phase 1 · Unknown · 2024-04 · NCT06618079
Phase 1 · Completed · 2024-04 · NCT06551740
Phase 1 · Completed · 2024-01 · NCT06552182
Show 19 more trials
Phase 3 · Completed · 2023-03 · NCT05743764
Phase 2 · Completed · 2022-03 · NCT05298449
Phase 3 · Completed · 2022-03 · NCT05289921
Phase 1 · Unknown · 2019-11 · NCT04415346
Phase 3 · Completed · 2019-05 · NCT04384991
Unknown · 2019-04 · NCT04224649
Phase 3 · Unknown · 2018-11 · NCT04081402
Phase 1 · Unknown · 2018-02 · NCT03495739
Phase 3 · Completed · 2018-01 · NCT03461575
Phase 1 · Unknown · 2018-01 · NCT03475719
Phase 3 · Unknown · 2017-11 · NCT03440671
Phase 1 · Completed · 2016-09 · NCT02902523
Phase 1/2 · Completed · 2016-09 · NCT02961673
Phase 3 · Completed · 2016-08 · NCT02893098
Phase 2 · Completed · 2016-03 · NCT02917512
Phase 4 · Completed · 2014-12 · NCT02696369
Phase 1 · Completed · 2014-09 · NCT02504606
Phase 2 · Completed · 2013-11 · NCT02491905
Phase 3 · Completed · 2013-05 · NCT02492412
Key disclosures
KRX KIND via OpenDARTPublications
PubMed · affiliation-matched- Efficacy of Prunella vulgaris on Male Lower Urinary Tract Symptoms: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
The world journal of men's health · 2026-10 · Kim TH, Kim S, Lee H 외 5
- A 12-week randomized, double-blind, placebo-controlled exploratory pilot study of HFN2-008 (heat-treated Bifidobacterium longum HN001) for adiposity reduction in overweight adults.
BMC nutrition · 2026-07 · Chai H, Kwak YG, Jang MR 외 4
- Improvement of Bladder Dysfunction by Quisqualis indica Extract in a Partial Bladder Outlet Obstruction Female Rat Model.
Pharmaceuticals (Basel, Switzerland) · 2026-07 · Kim J, Song JY, Kim K 외 5
- A Randomized Multicenter Study Comparing Low-Viscosity with Comparator 0.3% Hyaluronic Acid for the Treatment of Dry Eye Disease.
Ophthalmology and therapy · 2026-06 · Kim SJ, Kim JY, Kim DH 외 8
- A Novel Strain Bifidobacterium longum subsp. longum HN001 Ameliorates High-Fat Diet-Induced Obesity in Mice Through Microbiome-Associated Short-Chain Fatty Acids.
Probiotics and antimicrobial proteins · 2026-04 · Lee CH, Han Y, Ryu JY 외 6
- Development and Validation of a Standardized Lip Fullness Grading Scale.
Journal of cosmetic dermatology · 2026-03 · Choi SY, Jeong MK, Jung D 외 1
- Celery seed extract attenuates sarcopenic obesity and age-related sarcopenia by reducing intramuscular lipid accumulation in mice.
Frontiers in nutrition · 2026-01 · Shin SK, Jeong J, Kim MJ 외 4
- Anti-Atrophic Effects of Dichotomine B from Stellaria dichotoma During Starvation-Induced Skeletal Muscle Atrophy.
Molecules (Basel, Switzerland) · 2025-09 · Kim JY, Permpoon U, Lee JH 외 5
- Novel PDE9 inhibitors, KR39526 and KR39582, attenuate cardiac hypertrophy and fibrosis induced by pressure overload.
Journal of pharmacological sciences · 2025-08 · Lee JH, Park H, Lee SH 외 6
- Ameliorative Effects of Prunella vulgaris on Lower Urinary Tract Symptoms Induced by Benign Prostatic Hyperplasia in SD Rats via Nitric Oxide and Potassium Channels.
Pharmaceuticals (Basel, Switzerland) · 2025-03 · Nirujan BR, Kim J, Baek EB 외 7
Show 47 more publications
- Effect of Pinus koraiensis leaf extract on fatigue reduction and exercise performance: study protocol for a randomized, double-blind, placebo-controlled clinical trial.
Frontiers in medicine · 2025-01 · Choi Y, Yang C, Yoon JS 외 3
- Safety and efficacy of extracorporeal shockwave therapy on chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled study.
Prostate international · 2024-12 · Hur KJ, Bae WJ, Ha US 외 8
- Prunella vulgaris Extract Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia by Regulating Androgen Levels, Cell Proliferation, and Apoptosis.
Pharmaceuticals (Basel, Switzerland) · 2024-11 · Kumbukgahadeniya P, Baek EB, Hong EJ 외 5
- Improvement in Testosterone Production by Acorus gramineus for the Alleviation of Andropause Symptoms.
Journal of medicinal food · 2024-08 · Lee JY, Kim S, Kim H 외 5
- Potential of Lycii Radicis Cortex as an Ameliorative Agent for Skeletal Muscle Atrophy.
Pharmaceuticals (Basel, Switzerland) · 2024-04 · Son RH, Kim MI, Kim HM 외 6
- Chlorophyll a and novel synthetic derivatives alleviate atopic dermatitis by suppressing Th2 cell differentiation via IL-4 receptor modulation.
Clinical immunology (Orlando, Fla.) · 2024-01 · Kang KM, Han JH, Kim KS 외 13
- Post-harvest processed parsnip showed improved anti-oxidative capacity and protective potential against acrolein-induced inflammation in vitro and in vivo.
Frontiers in nutrition · 2024-01 · Lee K, Pan JH, Choi Y 외 14
- Extracorporeal Shockwave Therapy Alleviates Inflammatory Pain by Down-Regulating NLRP3 Inflammasome in Experimental Chronic Prostatitis and Chronic Pelvic Pain Syndrome.
The world journal of men's health · 2024-01 · Bae WJ, Shin D, Piao JJ 외 12
- The Neuroprotective Effects of Dendropanax morbifera Water Extract on Scopolamine-Induced Memory Impairment in Mice.
International journal of molecular sciences · 2023-11 · Kim SB, Ryu HY, Nam W 외 6
- Gemcitabine and rapamycin-loaded mixed polymeric thermogel for metastatic pancreatic cancer therapy.
Journal of controlled release : official journal of the Controlled Release Society · 2023-08 · Kim SY, Jo MJ, Yoon MS 외 12
- Chemical constituents of the Ajuga multiflora bunge and their protective effects on dexamethasone-induced muscle atrophy in C2C12 myotubes.
Natural product research · 2023-06 · Lee Y, Kim HM, Kim JH 외 8
- A Lignan from Alnus japonica Activates Myogenesis and Alleviates Dexamethasone-induced Myotube Atrophy.
Planta medica · 2023-04 · Lee H, Jeong JH, Hwang SH 외 2
- Fermented Perilla frutescens Ameliorates Depression-like Behavior in Sleep-Deprivation-Induced Stress Model.
International journal of molecular sciences · 2022-12 · Jee HJ, Ryu D, Kim S 외 4
- Preventive effects of the butanol fraction of Justicia procumbens L. against dexamethasone-induced muscle atrophy in C2C12 myotubes.
Heliyon · 2022-11 · Kim JY, Kim HM, Kim JH 외 8
- Repeated oral dose toxicity and genotoxicity of a standardized Quisqualis indica extract.
Toxicological research · 2022-10 · Kim JW, Kim H, Park H 외 4
- Luteolin-7-O-Glucuronide Improves Depression-like and Stress Coping Behaviors in Sleep Deprivation Stress Model by Activation of the BDNF Signaling.
Nutrients · 2022-08 · Ryu D, Jee HJ, Kim SY 외 3
- Protective Effect of Alpinia oxyphylla Fruit against tert-Butyl Hydroperoxide-Induced Toxicity in HepG2 Cells via Nrf2 Activation and Free Radical Scavenging and Its Active Molecules.
Antioxidants (Basel, Switzerland) · 2022-05 · Park CL, Kim JH, Jeon JS 외 9
- The mixture of Agrimonia pilosa Ledeb. and Salvia miltiorrhiza Bunge. extract produces analgesic and anti-inflammatory effects in a collagen-induced arthritis mouse model.
Animal cells and systems · 2022-01 · Feng JH, Jung JS, Hwang SH 외 9
- Bioassay-Guided Isolation of Two Eudesmane Sesquiterpenes from Lindera strychnifolia Using Centrifugal Partition Chromatography.
Molecules (Basel, Switzerland) · 2021-08 · Kim JH, Jeon JS, Kim JH 외 6
- Bioequivalence for a Fixed-Dose Combination Formulation of Bazedoxifene and Cholecalciferol Compared With the Corresponding Single Entities Given Together.
Clinical pharmacology in drug development · 2021-08 · Yun JN, Kan HS, Yeun JS 외 9
- The Anti-Inflammatory and the Antinociceptive Effects of Mixed Agrimonia pilosa Ledeb. and Salvia miltiorrhiza Bunge Extract.
Plants (Basel, Switzerland) · 2021-06 · Feng JH, Kim HY, Sim SM 외 9
- Computational Study on Selective PDE9 Inhibitors on PDE9-Mg/Mg, PDE9-Zn/Mg, and PDE9-Zn/Zn Systems.
Biomolecules · 2021-05 · Sivakumar D, Mudedla S, Jang S 외 5
- Effect of Extract and Synthesized Derivatives of Isolated Compound from Symplocos chinensis f. Pilosa Ohwi on Neuropathic Pain in Mice.
Molecules (Basel, Switzerland) · 2021-03 · Kim HY, Park SH, Zuo G 외 4
- Comparison of pharmacokinetics and safety characteristics between two olopatadine hydrochloride 5 mg tablet formulations in healthy Korean subjects.
Translational and clinical pharmacology · 2021-03 · Kim JH, Lee M, Kim N 외 6
- Efficient Separation of Phytochemicals from Muehlenbeckia volcanica (Benth.) Endl. by Polarity-Stepwise Elution Counter-Current Chromatography and Their Antioxidant, Antiglycation, and Aldose Reductase Inhibition Potentials.
Molecules (Basel, Switzerland) · 2021-01 · Zuo GL, Kim HY, Guillen Quispe YN 외 4
- The Effect of Lactobacillus acidophilus YT1 (MENOLACTO) on Improving Menopausal Symptoms: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.
Journal of clinical medicine · 2020-07 · Lim EY, Lee SY, Shin HS 외 9
- Anti-inflammatory effects of glycine thymosin β4 eye drops in experimental dry eye.
Biomedical reports · 2020-06 · Jin R, Li Y, Li L 외 6
- Pharmacokinetic comparison of two bazedoxifene acetate 20 mg tablet formulations in healthy Korean male volunteers.
Translational and clinical pharmacology · 2020-06 · Yeun JS, Kan HS, Lee M 외 6
- Skin Hydration Effects of Scale-Up Fermented Cyclopia intermedia against Ultraviolet B-Induced Damage in Keratinocyte Cells and Hairless Mice.
Evidence-based complementary and alternative medicine : eCAM · 2020-01 · Im AR, Yeon SH, Ji KY 외 3
- Quisqualis indica extract ameliorates low urinary tract symptoms in testosterone propionate-induced benign prostatic hyperplasia rats.
Laboratory animal research · 2020-01 · Kim DG, Kwon HJ, Lim JH 외 2
- Standardized Seed Extract of Quisqualis indica (HU-033) Attenuates Testosterone Propionate-Induced Benign Prostatic Hyperplasia via α1-Adrenergic Receptors and Androgen/Estrogen Signaling.
Preventive nutrition and food science · 2019-12 · Baek JM, Kim HJ, Nam MW 외 7
- Role of ANTXR1 in the regulation of RANKL-induced osteoclast differentiation and function.
Biochemical and biophysical research communications · 2019-03 · Baek JM, Kwak SC, Yoon KH 외 2
- Rosae multiflorae fructus extract and its four active components alleviate ovalbumin-induced allergic inflammatory responses via regulation of Th1/Th2 imbalance in BALB/c rhinitis mice.
Phytomedicine : international journal of phytotherapy and phytopharmacology · 2019-03 · Bui TT, Kwon DA, Choi DW 외 11
- Umbelliferone Prevents Lipopolysaccharide-Induced Bone Loss and Suppresses RANKL-Induced Osteoclastogenesis by Attenuating Akt-c-Fos-NFATc1 Signaling.
International journal of biological sciences · 2019-01 · Kwak SC, Baek JM, Lee CH 외 3
- Effect of Veratrum maackii on Testosterone Propionate-Induced Benign Prostatic Hyperplasia in Rats.
Biological & pharmaceutical bulletin · 2019-01 · Park HS, Seo CS, Wijerathne CU 외 7
- Protective effects of fermented honeybush (Cyclopia intermedia) extract (HU-018) against skin aging: a randomized, double-blinded, placebo-controlled study.
Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology · 2018-10 · Choi SY, Hong JY, Ko EJ 외 5
- Large-scale purification of unstable, water-soluble secologanic acid using centrifugal partition chromatography.
Phytochemical analysis : PCA · 2018-09 · Yeon SH, Jeon JS, Um KA 외 2
- Preventive Effects of a Probiotic Mixture in an Ovalbumin-Induced Food Allergy Model.
Journal of microbiology and biotechnology · 2018-01 · Shin HS, Eom JE, Shin DU 외 3
- Quisqualis indica Improves Benign Prostatic Hyperplasia by Regulating Prostate Cell Proliferation and Apoptosis.
Biological & pharmaceutical bulletin · 2017-12 · Ub Wijerathne C, Park HS, Jeong HY 외 8
- Structural analyses combined with small-angle X-ray scattering reveals that the retention of heme is critical for maintaining the structure of horseradish peroxidase under denaturing conditions.
Amino acids · 2017-04 · Cha HJ, Jang DS, Jin KS 외 1
- Effect of Novel Compound LX519290, a Derivative of l-allo Threonine, on Antioxidant Potential in Vitro and in Vivo.
International journal of molecular sciences · 2016-09 · Chun K, Alam MB, Son HU 외 1
- Protective effect of fermented Cyclopia intermedia against UVB-induced damage in HaCaT human keratinocytes.
BMC complementary and alternative medicine · 2016-07 · Im AR, Yeon SH, Lee JS 외 3
- Topical application of Scutellaria baicalensis suppresses 2,4-dinitrochlorobenzene-induced contact dermatitis.
Natural product research · 2016-01 · Kim TW, Choi JM, Kim MS 외 2
- Genetically obese (ob/ob) mice are resistant to the lethal effects of thioacetamide hepatotoxicity.
Toxicology and applied pharmacology · 2016-01 · Won YS, Song JW, Lim JH 외 5
- HS-23, a Lonicera japonica extract, reverses sepsis-induced immunosuppression by inhibiting lymphocyte apoptosis.
Journal of ethnopharmacology · 2015-08 · Kim SJ, Kim JS, Choi HS 외 5
- Magnolia officinalis attenuates free fatty acid-induced lipogenesis via AMPK phosphorylation in hepatocytes.
Journal of ethnopharmacology · 2014-11 · Seo MS, Hong SW, Yeon SH 외 6
- HS-23, Lonicera japonica extract, attenuates septic injury by suppressing toll-like receptor 4 signaling.
Journal of ethnopharmacology · 2014-08 · Kim SJ, Yoon SJ, Kim YM 외 4
Patents
KIPRIS · applicant-matchedPublished · 2026-02 · Application 1020260028799
Published · 2025-12 · Application 1020250206982
CN · Published · 2025-05 · Application 202580001757.9
PCT · Published · 2025-05 · Application PCT/KR2025/006288
Published · 2025-05 · Application 1020250060472
Published · 2024-12 · Application 1020240192181
Published · 2024-11 · Application 1020240173840
CN · Published · 2024-09 · Application 202480058413.7
EP · Published · 2024-09 · Application 24865898.1
PCT · Published · 2024-09 · Application PCT/KR2024/013975
Show 158 more patents
Published · 2024-09 · Application 1020240125922
Registered · 2024-06 · Application 1020240082879
Published · 2022-12 · Application 1020220182766
Withdrawn · 2022-12 · Application 1020220182763
Registered · 2022-12 · Application 1020220182519
Published · 2022-12 · Application 1020220177960
Published · 2022-12 · Application 1020220175667
Withdrawn · 2022-11 · Application 1020220149492
PCT · Published · 2022-09 · Application PCT/KR2022/014275
Withdrawn · 2022-06 · Application 1020220078386
Withdrawn · 2022-06 · Application 1020220070068
Withdrawn · 2021-12 · Application 1020210181345
Rejected · 2021-11 · Application 1020210168371
Rejected · 2021-11 · Application 1020210168370
Rejected · 2021-11 · Application 1020210157041
PCT · Published · 2021-11 · Application PCT/KR2021/016679
Registered · 2021-09 · Application 1020210128612
US · Published · 2021-09 · Application 18246773
PCT · Published · 2021-09 · Application PCT/KR2021/013161
Registered · 2021-09 · Application 1020210125029
Registered · 2021-08 · Application 1020210105227
Expired · 2021-03 · Application 1020210033276
Rejected · 2020-12 · Application 1020200181941
Rejected · 2020-12 · Application 1020200181533
Published · 2020-12 · Application 1020200181673
Registered · 2020-12 · Application 1020200178534
Rejected · 2020-12 · Application 1020200178538
Withdrawn · 2020-12 · Application 1020200178528
Registered · 2020-11 · Application 1020200163737
Withdrawn · 2020-11 · Application 1020200163739
Registered · 2020-10 · Application 1020200143063
Withdrawn · 2020-09 · Application 1020200117900
US · Registered · 2020-06 · Application 17629197
PCT · Published · 2020-06 · Application PCT/KR2020/008139
PCT · Published · 2020-04 · Application PCT/KR2020/005263
PCT · Published · 2020-04 · Application PCT/KR2020/005262
PCT · Published · 2020-04 · Application PCT/KR2020/005260
Registered · 2020-01 · Application 1020200001530
Rejected · 2019-12 · Application 1020190176969
Withdrawn · 2019-12 · Application 1020190173921
Registered · 2019-12 · Application 1020190173746
Registered · 2019-12 · Application 1020190174474
Expired · 2019-12 · Application 1020190173490
PCT · Published · 2019-12 · Application PCT/KR2019/017680
Registered · 2019-12 · Application 1020190166688
Rejected · 2019-12 · Application 1020190164688
PCT · Published · 2019-11 · Application PCT/KR2019/016670
Rejected · 2019-11 · Application 1020190146576
PCT · Published · 2019-11 · Application PCT/KR2019/014984
Registered · 2019-10 · Application 1020190131184
Registered · 2019-10 · Application 1020190124691
US · Registered · 2019-09 · Application 16574442
CN · Published · 2019-07 · Application 201980065912.8
US · Published · 2019-07 · Application 17266160
EP · Published · 2019-07 · Application 19847866.1
PCT · Published · 2019-07 · Application PCT/KR2019/009265
JP · Published · 2019-07 · Application 33506453
Registered · 2019-05 · Application 1020190056539
Registered · 2019-05 · Application 1020190056538
Rejected · 2019-05 · Application 1020190056540
Registered · 2019-03 · Application 1020190032114
CN · Published · 2019-01 · Application 201980010317.4
US · Published · 2019-01 · Application 16964640
EP · Published · 2019-01 · Application 19743233.9
PCT · Published · 2019-01 · Application PCT/KR2019/001055
Registered · 2018-12 · Application 1020180169938
Registered · 2018-12 · Application 1020180169937
Registered · 2018-12 · Application 1020180167385
Expired · 2018-12 · Application 1020180167067
Registered · 2018-12 · Application 1020180156324
Registered · 2018-11 · Application 1020180152738
Expired · 2018-08 · Application 1020180091887
PCT · Published · 2018-07 · Application PCT/KR2018/008665
PCT · Published · 2018-07 · Application PCT/KR2018/008664
Registered · 2018-07 · Application 1020180076711
Rejected · 2018-06 · Application 1020180068606
CN · Published · 2018-06 · Application 201810579913.1
CN · Published · 2018-06 · Application 201810579912.7
CN · Published · 2018-05 · Application 201880039418.X
US · Published · 2018-05 · Application 16621330
EP · Published · 2018-05 · Application 18818565.6
PCT · Published · 2018-05 · Application PCT/KR2018/006030
JP · Published · 2018-05 · Application 31569745
Expired · 2018-02 · Application 1020180019456
Rejected · 2018-02 · Application 1020180013506
Expired · 2018-01 · Application 1020180010055
Rejected · 2018-01 · Application 1020180002389
PCT · Published · 2017-12 · Application PCT/KR2017/015478
Registered · 2017-12 · Application 1020170178724
PCT · Published · 2017-12 · Application PCT/KR2017/014807
PCT · Published · 2017-12 · Application PCT/KR2017/014806
Registered · 2017-12 · Application 1020170172397
Registered · 2017-12 · Application 1020170172396
Rejected · 2017-10 · Application 1020170131038
Rejected · 2017-10 · Application 1020170131040
Registered · 2017-09 · Application 1020170118657
Registered · 2017-09 · Application 1020170118658
Rejected · 2017-09 · Application 1020170118656
Expired · 2017-06 · Application 1020170074962
Registered · 2017-06 · Application 1020170073013
Registered · 2017-06 · Application 1020170073019
Withdrawn · 2017-03 · Application 1020170030784
Rejected · 2017-02 · Application 1020170020494
Registered · 2016-12 · Application 1020160182360
Rejected · 2016-12 · Application 1020160178794
Withdrawn · 2016-12 · Application 1020160175890
Withdrawn · 2016-12 · Application 1020160172802
Withdrawn · 2016-12 · Application 1020160170687
Registered · 2016-09 · Application 1020160121551
Registered · 2016-07 · Application 1020160094706
Withdrawn · 2016-01 · Application 1020160004258
CN · Published · 2015-12 · Application 201580072075.3
Registered · 2015-12 · Application 1020150191296
US · Registered · 2015-12 · Application 15540896
EP · Registered · 2015-12 · Application 15875763.3
PCT · Published · 2015-12 · Application PCT/KR2015/014580
PCT · Published · 2015-12 · Application PCT/KR2015/014275
Registered · 2015-12 · Application 1020150186798
Rejected · 2015-12 · Application 1020150186800
Rejected · 2015-12 · Application 1020150186174
Rejected · 2015-12 · Application 1020150185461
PCT · Published · 2015-11 · Application PCT/KR2015/012595
CN · Published · 2015-10 · Application 201580056326.9
US · Registered · 2015-10 · Application 15519497
EP · Registered · 2015-10 · Application 15850677.4
PCT · Published · 2015-10 · Application PCT/KR2015/011048
Expired · 2015-07 · Application 1020150103209
Registered · 2014-12 · Application 1020140188274
Registered · 2014-11 · Application 1020140168980
Registered · 2014-11 · Application 1020140163585
Rejected · 2013-01 · Application 1020130007695
Rejected · 2013-01 · Application 1020130007694
CN · Published · 2013-01 · Application 201380016584
US · Registered · 2013-01 · Application 14398012
EP · Registered · 2013-01 · Application 13784924.6
JP · Registered · 2013-01 · Application 27508845
CN · Published · 2012-11 · Application 201280072577
US · Published · 2012-11 · Application 14397468
EP · Published · 2012-11 · Application 12875567.5
CN · Published · 2012-06 · Application 201280028177
PCT · Published · 2012-06 · Application PCT/KR2012/004578
Registered · 2012-04 · Application 1020120044441
CN · Published · 2009-12 · Application 200980158822
EP · Published · 2009-12 · Application 09844984.6
Registered · 2009-07 · Application 1020090063514
Expired · 2009-05 · Application 1020090044995
Rejected · 2008-09 · Application 2020080012359
Expired · 2008-07 · Application 1020080069271
Rejected · 2008-07 · Application 2020080009168
Rejected · 2007-12 · Application 1020070126568
Rejected · 2007-10 · Application 1020070108336
Expired · 2006-11 · Application 1020060113786
Registered · 2006-11 · Application 1020060113784
Expired · 2006-09 · Application 1020060084661
Expired · 2006-07 · Application 1020060072234
Expired · 2005-12 · Application 1020050118482
Rejected · 2005-05 · Application 1020050044813
Expired · 1998-10 · Application 1019980043104
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive2
- OpenAIOAI-SearchBot88
- GoogleGoogleOther8
- PerplexityPerplexityBot3
- AnthropicClaudeBot2
Measured since Aug 26, 2026 · 4 AI engines · last read Oct 9, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for HUONS CO., LTD. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies approved for the same productsPharma & CDMO
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
KOSDAQ-listed aesthetics and CMO company behind the Elravie/Revolax hyaluronic-acid fillers and Leedstox botulinum toxin.
KOSDAQ-listed medical device company producing human tissue implants Bella Cell HD and SureFuse.
CAREGEN develops peptide-based cosmeceuticals sold in 130 countries and ophthalmic drug candidates CG-P5 and CG-T1.
KOSDAQ-listed healthcare company selling the Cissus weight-management ingredient and Sallimbaekseo household products.
KOSPI-listed pharmaceutical company behind the combination drugs Amosartan (hypertension) and Rosuzet (dyslipidemia).
Hugel is a KOSDAQ-listed pharmaceutical/CDMO company making a botulinum toxin injectable and the hyaluronic acid filler The Chaeum.
KOSDAQ-listed pharmaceutical company producing a diverse, low-volume portfolio of metabolic disease drugs, wellness injections, and veterinary medicines.
Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.
KOSDAQ-listed medical device company producing HIFU devices DOUBLO/V-RO and the Synerjet non-invasive drug delivery system for aesthetic dermatology.
Spun off and listed in 2013, Chong Kun Dang out-licensed its HDAC6 inhibitor CKD-510 to Novartis in a deal worth about KRW 1.7 trillion.
Uses AI analysis of medical imaging to 3D-print patient-specific surgical guides, implants, and simulators.
KOSDAQ-listed comprehensive healthcare and pharmaceutical company behind the gum treatment Insadol and the wound-care ointment Madecassol.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition